利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12083 条记录 (耗时 0.082 秒)

    ANTIFUNGAL AGENTS USED IN COMBINATION
    82.
    发明申请
    ANTIFUNGAL AGENTS USED IN COMBINATION 有权

    公开(公告)号：US20220202833A1

    公开(公告)日：2022-06-30

    申请号：US17399015

    申请日：2021-08-10

    申请人： Scynexis, Inc.

    发明人： David A. Angulo Gonzalez

    IPC分类号： A61K31/58 ,  A61K31/4439 ,  A61P31/10 ,  A61K31/4196 ,  A61K45/06 ,  A61K31/496 ,  A61K31/506 ,  A61K31/7048

    摘要： The present invention relates to the use of enfumafungin derivative triterpenoid antifungal compounds in combination with other antifungal agents such azoles, polyenes, lipopeptides, and allylamides to treat fungal diseases. More particularly, the invention relates to antifungal combinations of enfumafungin derivative triterpenoids which are inhibitors of (1,3)-β-D-glucan synthesis, in combination with other antifungal agents such as mold-active agents that have activity against molds, including but not limited to voriconazole, isavuconazole, posaconazole, itraconazole and amphotericin B, for the treatment and/or prevention of infections caused by molds.

    PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HAVING DOUBLE-RELEASE PROFILE
    83.
    发明申请
    PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HAVING DOUBLE-RELEASE PROFILE 有权

    公开(公告)号：US20220202795A1

    公开(公告)日：2022-06-30

    申请号：US17600639

    申请日：2020-04-01

    申请人： HANMI PHARM. CO., LTD

    发明人： Hyuk Jun CHO ,  Taek KWON ,  Ho Taek IM ,  Yong ll KIM ,  Jin A JUNG ,  Han Kil SON ,  Sung Hee HONG

    IPC分类号： A61K31/4439 ,  A61K9/28

    摘要： The present disclosure relates to a pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, and particularly to a pharmaceutical composition which exhibits a dual release profile of immediate release and sustained release so that long-term efficacy can be sustained. The pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, according to the present disclosure, can secure bioavailability equivalent to that of existing esomeprazole immediate-release/enteric-release formulations, and can maintain long-term efficacy due to the dual release profile thereof even when administered once a day, thus preventing the occurrence of nocturnal acid breakthrough, and accordingly, can be effectively used as a therapeutic agent for nocturnal acid breakthrough.

    ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFOR
    85.
    发明申请
    ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFOR 有权

    公开(公告)号：US20220202779A1

    公开(公告)日：2022-06-30

    申请号：US17584951

    申请日：2022-01-26

    申请人： Hua Medicine (Shanghai) Ltd.

    发明人： Li Chen ,  Yongguo Li ,  Gaosen Wang

    IPC分类号： A61K31/4155 ,  A61K9/20 ,  A61K31/426 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497

    摘要： Disclosed is a solid dispersion and a preparation method therefor. The solid dispersion contains a glucokinase activator, an isotopic label thereof, or a medicinal salt thereof and a polymer support. Further disclosed is a solid dispersion composition containing the solid dispersion and an excipient. Also disclosed is an oral preparation of the glucokinase activator, containing the solid dispersion or the solid dispersion composition. Also disclosed is a tablet and a capsule of the glucokinase activator and a preparation method therefor. In addition, also disclosed is the uses of the solid dispersion, the solid dispersion composition and the oral preparations comprising the tablet and the capsule, which can be used for treating and/or preventing selected diseases or medical conditions and especially one or more diseases selected from type I diabetes mellitus, type II diabetes mellitus, impaired glucose tolerance, impaired fasting glucose and hyperglycemia.

    PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
    89.
    发明申请
    PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM 有权

    公开(公告)号：US20220175927A1

    公开(公告)日：2022-06-09

    申请号：US17678495

    申请日：2022-02-23

    申请人： AXSOME THERAPEUTICS, INC.

    发明人： Herriot Tabuteau

    IPC分类号： A61K47/02 ,  A61K31/5415 ,  A61K31/4439 ,  A61K9/00 ,  A61K47/69 ,  A61K47/40 ,  A61K9/20 ,  C08B37/16 ,  A61K45/06

    摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.